CY1121924T1 - Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα - Google Patents

Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα

Info

Publication number
CY1121924T1
CY1121924T1 CY20191100571T CY191100571T CY1121924T1 CY 1121924 T1 CY1121924 T1 CY 1121924T1 CY 20191100571 T CY20191100571 T CY 20191100571T CY 191100571 T CY191100571 T CY 191100571T CY 1121924 T1 CY1121924 T1 CY 1121924T1
Authority
CY
Cyprus
Prior art keywords
treatment
virus infection
hepatitis virus
delta hepatitis
infection
Prior art date
Application number
CY20191100571T
Other languages
English (en)
Inventor
David Cory
Ingrid Choong
Jeffrey S. Glenn
Original Assignee
Eiger Biopharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals, Inc. filed Critical Eiger Biopharmaceuticals, Inc.
Publication of CY1121924T1 publication Critical patent/CY1121924T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ο αναστολέας της προνυλτρανσφεράσης λοναφαρνίμπη και ο αναστολέας του CYP3A4 ριτοναβίρη χρησιμοποιούνται σε συνδυασμό για τη θεραπεία της λοίμωξης από τον ιό της ηπατίτιδας δέλτα (HDV). Η λοίμωξη HDV αντιμετωπίζεται με χορήγηση από του στόματος σε έναν ασθενή μίας θεραπευτικώς αποτελεσματικής ποσότητας λοναφαρνίμπης και μιας θεραπευτικώς αποτελεσματικής ποσότητας ενός αναστολέα του CYP3A4 για τουλάχιστον 30 ημέρες. Προαιρετικά η θεραπεία περιλαμβάνει προφυλακτική χορήγηση ενός ή περισσοτέρων παραγόντων τροποποίησης του γαστρεντερικού.
CY20191100571T 2014-05-01 2019-05-29 Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα CY1121924T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461987315P 2014-05-01 2014-05-01
US201462044766P 2014-09-02 2014-09-02
US201462073413P 2014-10-31 2014-10-31
US201562151349P 2015-04-22 2015-04-22
PCT/US2015/028933 WO2015168648A1 (en) 2014-05-01 2015-05-01 Treatment of hepatitis delta virus infection

Publications (1)

Publication Number Publication Date
CY1121924T1 true CY1121924T1 (el) 2020-10-14

Family

ID=54359409

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100571T CY1121924T1 (el) 2014-05-01 2019-05-29 Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα

Country Status (13)

Country Link
EP (2) EP3137078B1 (el)
JP (1) JP6490800B2 (el)
KR (2) KR20170005827A (el)
CN (2) CN111265525A (el)
CY (1) CY1121924T1 (el)
DK (1) DK3137078T3 (el)
ES (1) ES2728405T3 (el)
HU (1) HUE044606T2 (el)
LT (1) LT3137078T (el)
PL (1) PL3137078T3 (el)
PT (1) PT3137078T (el)
SI (1) SI3137078T1 (el)
WO (1) WO2015168648A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
KR20180073652A (ko) * 2015-11-04 2018-07-02 아이거 바이오파마슈티컬스 인코포레이티드 델타 간염 바이러스 감염의 치료
JP2019505553A (ja) * 2016-02-19 2019-02-28 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
US11801371B2 (en) 2017-03-01 2023-10-31 National University Of Singapore Microneedle device

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
WO2002028831A1 (en) * 2000-10-02 2002-04-11 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2005117864A1 (en) * 2004-05-28 2005-12-15 Astrazeneca Ab Combination product comprising anastrozole and a dual prenyl transferase inhibitor
US20080021078A1 (en) 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
JP2009530382A (ja) * 2006-03-23 2009-08-27 シェーリング コーポレイション Ｈｃｖプロテアーゼインヒビターとｃｙｐ３ａ４インヒビターとの組み合わせ、および関連する処置方法
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008137692A1 (en) * 2007-05-03 2008-11-13 Link Medicine Corporation Treatment of synucleinopathies
US20090087483A1 (en) 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
WO2010009432A1 (en) 2008-07-17 2010-01-21 Horizon Therapeutics, Inc. Nsaid dose unit formulations with h2-receptor antagonists and methods of use
SI2421527T1 (sl) * 2009-04-25 2018-09-28 F. Hoffmann-La Roche Ag Metode za izboljšanje farmakokinetike
WO2011088126A2 (en) 2010-01-13 2011-07-21 Eiger Biopharmaceuticals, Inc. Treatment of viral infection with prenyltransferase inhibitors

Also Published As

Publication number Publication date
KR20170005827A (ko) 2017-01-16
PT3137078T (pt) 2019-06-11
EP3137078A4 (en) 2017-11-15
PL3137078T3 (pl) 2019-08-30
CN111265525A (zh) 2020-06-12
LT3137078T (lt) 2019-06-25
KR20230062688A (ko) 2023-05-09
EP3137078B1 (en) 2019-03-20
EP3137078A1 (en) 2017-03-08
DK3137078T3 (da) 2019-06-11
JP2017514911A (ja) 2017-06-08
JP6490800B2 (ja) 2019-03-27
ES2728405T3 (es) 2019-10-24
CN106535895A (zh) 2017-03-22
CN106535895B (zh) 2020-02-28
WO2015168648A1 (en) 2015-11-05
EP3620163A1 (en) 2020-03-11
HUE044606T2 (hu) 2019-11-28
SI3137078T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
CY1121924T1 (el) Θεραπεια της λοιμωξης απο τον ιο της ηπατιτιδας δελτα
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1123962T1 (el) Μεθοδοι και φαρμακευτικες συνθεσεις για την αγωγη της λοιμωξης απο τον ιο της ηπατιτιδας β
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
PH12017550022A1 (en) Phosphoramidates for the treatment of hepatitis b virus
EA201691440A1 (ru) Производные азепана и способы лечения инфекций гепатита в
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
CR20170424A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsula del vhb
MX2018005230A (es) Terapia de combinacion de un inhibidor del ensamble de la capside del hbv y un interferon.
EA201690979A1 (ru) Производные азепана и способы лечения инфекций гепатита в
CY1120607T1 (el) Παραγωγα ισοϊνδολινης για χρηση στη θεραπεια μιας ιικης μολυνσης
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
EA201590703A1 (ru) Ингибиторы mek при лечении вирусных заболеваний
EA201791736A1 (ru) Комбинированная терапия для лечения рака
CY1123532T1 (el) Αναστολεις του gingipain λυσινης
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
CY1121566T1 (el) Νευροπροστατευτικο και ενδειξη αυτου
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CY1122923T1 (el) Παραγωγα 3-((ετερο-)αρυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου